Perspective Therapeutics to Participate in Upcoming February Investor Conferences

Rhea-AI Summary

Perspective Therapeutics (NYSE AMERICAN: CATX), a radiopharmaceutical company focused on advanced cancer treatments, has announced its participation in two major investor conferences in February 2025.

The company will attend Oppenheimer's 35th Annual Healthcare Life Sciences Conference, featuring a virtual fireside chat on Wednesday, February 12, 2025, from 2:00 p.m. to 2:30 p.m. ET. Additionally, they will participate in the B. Riley Securities Precision Oncology & Radiopharma Investor Conference in New York, NY on Friday, February 28, 2025.

Senior leadership team members will be available for one-on-one meetings with investors at both events. Webcasts will be accessible live and archived for 90 days through the Investors page on Perspective's website.

SEATTLE, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming investor conferences.

Oppenheimer's 35th Annual Healthcare Life Sciences Conference – Fireside Chat
Date: Wednesday, February 12, 2025
Time: 2:00 p.m. - 2:30 p.m. ET
Location: Virtual

B. Riley Securities Precision Oncology & Radiopharma Investor Conference
Date: Friday, February 28, 2025
Location: New York, NY

Webcast events can be accessed live, and replays will be archived for 90 days and available through the Investors page on the Perspective website at https://perspectivetherapeutics.com/investor-center.

About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc., is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha emitting isotope ²¹²Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moeities. The Company is also developing complementary imaging diagnostics that incorporate the same targeting moeities which provide the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity.

The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-α-NET) programs have entered Phase 1/2a imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several leading academic institutions. The Company has also developed a proprietary ²¹²Pb generator to secure key isotopes for clinical trial and commercial operations.

For more information, please visit the Company's website at www.perspectivetherapeutics.com.

Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include statements concerning, among other things, the Company's ability to pioneer advanced treatment applications for cancers throughout the body; the ability of the Company's proprietary technology utilizing the alpha emitting isotope ²¹²Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moeities; the Company's prediction that complementary imaging diagnostics that incorporate certain targeting moeities provide the opportunity to personalize treatment and optimize patient outcomes; the Company's belief that its "theranostic" approach enables the ability to see a specific tumor and then treat it to potentially improve efficacy and minimize toxicity; the Company's ability to develop a proprietary ²¹²Pb generator to secure key isotopes for clinical trial and commercial operations; and other statements that are not historical fact.

These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Certain factors that may cause the Company's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC"), in the Company's other filings with the SEC, and in the Company's future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Media and Investor Relations Contacts:

Perspective Therapeutics IR:
Annie J. Cheng, CFA
ir@perspectivetherapeutics.com

Russo Partners, LLC
Nic Johnson
PerspectiveIR@russopr.com

FAQ

When is Perspective Therapeutics (CATX) presenting at the Oppenheimer Healthcare Conference in 2025?

Perspective Therapeutics will present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference on Wednesday, February 12, 2025, from 2:00 p.m. to 2:30 p.m. ET in a virtual fireside chat format.

Where can investors watch CATX's February 2025 conference presentations?

Investors can access the webcasts live and view replays for 90 days through the Investors page on Perspective Therapeutics' website at perspectivetherapeutics.com/investor-center.

Which investor conferences is CATX attending in February 2025?

CATX is attending two conferences: Oppenheimer's 35th Annual Healthcare Life Sciences Conference on February 12 and the B. Riley Securities Precision Oncology & Radiopharma Investor Conference on February 28, 2025.

Will CATX management be available for one-on-one meetings at the February 2025 conferences?

Yes, members of Perspective Therapeutics' senior leadership team will be available for one-on-one meetings with investors at both February conferences.